(ALGN) Align Technology - Ratings and Ratios
Clear Aligners, Intraoral Scanners, CAD/CAM Software, Retainers, 3D Printing
ALGN EPS (Earnings per Share)
ALGN Revenue
Description: ALGN Align Technology
Align Technology Inc (NASDAQ:ALGN) is a leading provider of innovative orthodontic and restorative dentistry solutions, including clear aligners, intraoral scanners, and CAD/CAM services. The companys flagship product, Invisalign, has revolutionized the orthodontic industry with its clear aligner technology, catering to a wide range of patients from teens to adults with various orthodontic needs.
From a business perspective, Align Technology operates through two main segments: Clear Aligner and Imaging Systems and CAD/CAM Services. The Clear Aligner segment dominates the companys revenue, driven by the popularity of Invisalign products, which offer a comprehensive range of treatment options for different patient needs. The Imaging Systems and CAD/CAM Services segment provides iTero intraoral scanning systems and software solutions, enhancing the companys ecosystem for dental professionals.
To gauge Align Technologys performance, key performance indicators (KPIs) such as revenue growth, gross margin, and customer acquisition costs are crucial. The companys revenue growth has been driven by the increasing adoption of Invisalign and iTero products, with a strong presence in both the orthodontic and restorative dentistry markets. Gross margin is another important metric, reflecting the companys ability to maintain pricing power and manage production costs. Additionally, metrics such as the number of cases treated with Invisalign, iTero scanner adoption rates, and customer retention rates provide valuable insights into the companys operational performance.
From a financial perspective, Align Technologys market capitalization stands at approximately $14.3 billion, with a forward P/E ratio of 19.27, indicating a relatively high growth expectation. The companys return on equity (RoE) is around 10.67%, suggesting a decent return for shareholders. To further analyze the companys financial health, metrics such as operating cash flow, debt-to-equity ratio, and research and development (R&D) expenses as a percentage of revenue can provide a more comprehensive picture.
ALGN Stock Overview
| Market Cap in USD | 9,536m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 2001-01-26 |
ALGN Stock Ratings
| Growth Rating | -77.3% |
| Fundamental | 82.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -55.5% |
| Analyst Rating | 4.0 of 5 |
ALGN Dividends
Currently no dividends paidALGN Growth Ratios
| Growth Correlation 3m | -70.9% |
| Growth Correlation 12m | -81.7% |
| Growth Correlation 5y | -79.9% |
| CAGR 5y | -17.35% |
| CAGR/Max DD 3y | -0.26 |
| CAGR/Mean DD 3y | -0.55 |
| Sharpe Ratio 12m | -0.64 |
| Alpha | 0.07 |
| Beta | 0.000 |
| Volatility | 45.36% |
| Current Volume | 757.4k |
| Average Volume 20d | 1222.3k |
| Stop Loss | 126.1 (-4.3%) |
| Signal | -0.28 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (437.6m TTM) > 0 and > 6% of Revenue (6% = 237.9m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA 4.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.41% (prev 9.44%; Δ 1.97pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 731.1m > Net Income 437.6m (YES >=105%, WARN >=100%) |
| Net Debt (-778.1m) to EBITDA (793.4m) ratio: -0.98 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (72.6m) change vs 12m ago -3.50% (target <= -2.0% for YES) |
| Gross Margin 69.79% (prev 69.82%; Δ -0.04pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 64.07% (prev 64.02%; Δ 0.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 595.5 (EBITDA TTM 793.4m / Interest Expense TTM 1.07m) >= 6 (WARN >= 3) |
Altman Z'' 3.57
| (A) 0.07 = (Total Current Assets 2.45b - Total Current Liabilities 2.00b) / Total Assets 6.22b |
| (B) 0.39 = Retained Earnings (Balance) 2.43b / Total Assets 6.22b |
| (C) 0.10 = EBIT TTM 637.8m / Avg Total Assets 6.19b |
| (D) 1.08 = Book Value of Equity 2.49b / Total Liabilities 2.31b |
| Total Rating: 3.57 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 82.37
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 7.55% = 3.78 |
| 3. FCF Margin 17.11% = 4.28 |
| 4. Debt/Equity 0.09 = 2.50 |
| 5. Debt/Ebitda 0.43 = 2.36 |
| 6. ROIC - WACC (= 5.57)% = 6.96 |
| 7. RoE 11.29% = 0.94 |
| 8. Rev. Trend 75.48% = 5.66 |
| 9. EPS Trend 77.99% = 3.90 |
What is the price of ALGN shares?
Over the past week, the price has changed by -3.02%, over one month by -9.05%, over three months by -27.78% and over the past year by -47.18%.
Is Align Technology a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALGN is around 93.92 USD . This means that ALGN is currently overvalued and has a potential downside of -28.75%.
Is ALGN a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 6
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the ALGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 186.4 | 41.4% |
| Analysts Target Price | 186.4 | 41.4% |
| ValueRay Target Price | 107.1 | -18.7% |
Last update: 2025-09-15 04:30
ALGN Fundamental Data Overview
CCE Cash And Equivalents = 901.2m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 22.223
P/E Forward = 12.2399
P/S = 2.4052
P/B = 2.4372
P/EG = 0.78
Beta = 1.654
Revenue TTM = 3.96b USD
EBIT TTM = 637.8m USD
EBITDA TTM = 793.4m USD
Long Term Debt = 310.8m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 32.5m USD (from shortTermDebt, last quarter)
Debt = 343.4m USD (Calculated: Short Term 32.5m + Long Term 310.8m)
Net Debt = -778.1m USD (from netDebt column, last quarter)
Enterprise Value = 8.98b USD (9.54b + Debt 343.4m - CCE 901.2m)
Interest Coverage Ratio = 595.5 (Ebit TTM 637.8m / Interest Expense TTM 1.07m)
FCF Yield = 7.55% (FCF TTM 678.3m / Enterprise Value 8.98b)
FCF Margin = 17.11% (FCF TTM 678.3m / Revenue TTM 3.96b)
Net Margin = 11.04% (Net Income TTM 437.6m / Revenue TTM 3.96b)
Gross Margin = 69.79% ((Revenue TTM 3.96b - Cost of Revenue TTM 1.20b) / Revenue TTM)
Tobins Q-Ratio = 3.61 (Enterprise Value 8.98b / Book Value Of Equity 2.49b)
Interest Expense / Debt = 0.31% (Interest Expense 1.07m / Debt 343.4m)
Taxrate = 30.81% (187.6m / 609.0m)
NOPAT = 441.3m (EBIT 637.8m * (1 - 30.81%))
Current Ratio = 1.23 (Total Current Assets 2.45b / Total Current Liabilities 2.00b)
Debt / Equity = 0.09 (Debt 343.4m / last Quarter total Stockholder Equity 3.91b)
Debt / EBITDA = 0.43 (Net Debt -778.1m / EBITDA 793.4m)
Debt / FCF = 0.51 (Debt 343.4m / FCF TTM 678.3m)
Total Stockholder Equity = 3.88b (last 4 quarters mean)
RoA = 7.04% (Net Income 437.6m, Total Assets 6.22b )
RoE = 11.29% (Net Income TTM 437.6m / Total Stockholder Equity 3.88b)
RoCE = 15.23% (Ebit 637.8m / (Equity 3.88b + L.T.Debt 310.8m))
RoIC = 11.39% (NOPAT 441.3m / Invested Capital 3.88b)
WACC = 5.82% (E(9.54b)/V(9.88b) * Re(6.02%)) + (D(343.4m)/V(9.88b) * Rd(0.31%) * (1-Tc(0.31)))
Shares Correlation 3-Years: -96.97 | Cagr: -0.68%
Discount Rate = 6.02% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.78% ; FCFE base≈568.9m ; Y1≈588.6m ; Y5≈668.4m
Fair Price DCF = 162.1 (DCF Value 11.75b / Shares Outstanding 72.5m; 5y FCF grow 3.56% → 3.0% )
EPS Correlation: 77.99 | EPS CAGR: 24.60% | SUE: -0.68 | # QB: 0
Revenue Correlation: 75.48 | Revenue CAGR: 4.78%
Additional Sources for ALGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle